What you fail to note is that the directors take all those fees as stock. If you look at the last cash flow report they had the director fees listed however they are not deducted from the total spend. So the cash churn is less than you think.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025